159 Diagnostic utility of molecular and imaging biomarkers 2 Table 27. Estimated pooled test performance of a 7-gene mutation panel in indeterminate thyroid nodules ni test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Nikiforov 2011* 461 63 398 0 461 (100%) 55 8 38 360 20% 59 (48-69) 98 (96-99) 27.20 (13.43-55.11) 0.42 (0.33-0.53) Mancini 2012 48 11 37 0 38 (79%) 5 3 4 26 19% 56 (21-86) 90 (73-98) 5.37 (1.58-18.20) 0.50 (0.24-1.04) Ohori 2013* 424 64 320 40 384 (100%) 60 4 54 266 27% 53 (43-62) 99 (96-100) 35.53 (13.23-95.43) 0.48 (0.40-0.58) BeaudenonHuibregtse 2014* 80 14 66 0 41 (51%) 8 3 9 21 21% 47 (23-72) 88 (68-97) 3.76 (1.17-12.16) 0.61 (0.38-0.97) Eszlinger 2014 (1) 164 21 120 23 141 (100%) 4 17 18 102 13% 18 (5-40) 86 (78-91) 1.27 (0.47-3.42) 0.95 (0.77-1.18) Eszlinger 2014 (2) 125 13 111 1 64 (52%) 3 4 6 51 7% 33 (7-70) 93 (82-98) 4.58 (1.22-17.17) 0.72 (0.45-1.15) Eszlinger 2015 163 31 127 5 158 (100%) 22 9 23 104 28% 49 (34-64) 92 (85-96) 6.14 (3.07-12.29) 0.56 (0.42-0.74) Giovanella 2015 61 7 54 0 61 (100%) 4 3 12 42 26% 25 (7-52) 93 (82-99) 3.75 (0.94-14.97) 0.80 (0.60-1.08) Labourier 2015* 109 34 75 0 109 (100%) 24 10 11 64 32% 69 (51-83) 86 (77-93) 5.07 (2.73-9.42) 0.36 (0.22-0.60) Valderrabano 2016* 105 15 83 7 56 (57%) 10 3 9 34 18% 53 (29-76) 92 (78-98) 6.49 (2.02-20.82) 0.52 (0.32-0.84) POOLED RESULTS 1,740 273 1,391 76 1.513 (90.9%) 195 64 184 1,070 21.8% 47.4 (38.0-56.9) 93.4 (89.4-96.0) 7.22 (4.08-12.76) 0.56 (0.46-0.68) *: study applied miRInformĀ® test. FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw